Drug Trial Radar · NCT00077584
Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma
Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
188
Actual
Start
Oct 2003
Primary completion
Mar 2005
Study completion May 2005
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Feb 11, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In an earlier clinical trial, RAPIDS-1, conducted in scleroderma patients with or without digital ulcers at baseline, bosentan significantly reduced the number of new digital ulcers versus placebo. The purpose of the present trial (RAPIDS-2) is to evaluate the prevention and healing effects of bosentan versus placebo on digital ulcers over a 24-week treatment period.
Conditions
- Digital Ulcers
- Systemic Sclerosis
Interventions
Bosentan 62.5 mgDrug
Oral tablets containing 62.5 mg of bosentan
Bosentan 125 mgDrug
Oral tablets containing 125 mg of bosentan
PlaceboDrug
Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to complete healing of the cardinal ulcer (CU) up to Week 24 in patients with CU healing maintained for 12 weeksTime frame: 24 weeks
- Total number of new digital ulcers per patient up to Week 24Time frame: 24 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.